Skip to main content
Publications
Pesantez D, Hoorn ST, Machado I, Garcia-Albeniz X , Rodriguez-Salas N, Heredia-Soto V, Vinal D, Pericay C, Garcia-Carbonero R, Losa F, Alonso V, Vera R, Batlle JF, Gallego J, Salud A, Nogue M, Layos L, Montagut C, Capdevila J, Vermeulen L, Maurel J, Fernandez-Martos C. Total neoadjuvant therapy with or without aflibercept in rectal cancer: three-year results of GEMCAD-1402 . J Natl Cancer Inst. 2023 Dec 6;115(12):1497-505. doi: 10.1093/jnci/djad120
Richardson D , Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M , Odom D , Hollis K , Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application . Breast Cancer Res Treat. 2021 May;187(1):113-24. doi: 10.1007/s10549-020-06082-7
Montano CB, Patel M, Jain R, Masand PS, Harrington A, Gillard P, Sullivan K, McElroy SL, Brown TM , Nelson L , McIntyre RS. The rapid mood screener: a novel and pragmatic screener tool for bipolar I disorder . CNS Spectr. 2021 Apr;26(2):167-8. doi: 10.1017/S1092852920002709
Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L , Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE. BRCA testing and outcomes in women with breast cancer . Breast Cancer Res Treat. 2021 Apr;186(3):839-50. doi: 10.1007/s10549-020-06038-x
McSweeney L, Breckons M, Fattakhova G, Oluboyede Y, Vale L, Ternent L, Balp M-M, Doward L , Brass CA, Beyer F, Sanyal A, Anstee QM. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis . JHEP Rep. 2020 Mar 6;2(3). doi: 10.1016/j.jhepr.2020.100099
Liede A, Mansfield CA , Metcalfe KA, Price MA, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment . Breast Cancer Res Treat. 2017 Sep;165(2):433-44. doi: 10.1007/s10549-017-4332-3.
Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Perez-Carrion R, Carmona A, Ayuso JR, Ripolles T, Bouzas R, Gironella M, Garcia-Albeniz X , Feliu J, Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial . Tumour Biol. 2017 Jun;39(6). doi: 10.1177/1010428317705509
Dine JL , O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl . Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z.
Pavlovic M, Arnal-Estape A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albeniz X , Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis RR. Enhanced MAF oncogene expression and breast cancer bone metastasis . J Natl Cancer Inst. 2015 Sep 15;107(12):djv256. doi: 10.1093/jnci/djv256
Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA , Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascon P, Mellado B, Molina R. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients . Tumour Biol. 2007;28(5):264-82.